The data were collected by means of a structured questionnaire, applied in loco as an HDAC inhibitor drugs interview with the responsible for the Hospital Pharmacy service. The thematic discourse analysis technique was employed for data analysis. The results pointed out that none of the hospitals has a committee of pharmaceutics and therapeutics and, in about 70% of the hospitals, the drug selection and standardization is carried out exclusively by the physicians. Concerning to the prescription of the non-standardized drugs, in 80 % of the studied cases, the doctor’s opinion prevailed and, in only 2 hospitals, there was

a pre-defined and consensual policy for the inclusion of drugs that in the list of standardized ones.”
“Objectives:

To evaluate the contribution made by fetal echocardiography in identifying Down’s syndrome (DS) and other chromosomal disorders in a stepwise sequential screening method (first step: combined test (CT), second step: modified genetic sonography (MGS) (major malformation and nuchal fold)), for DS in the general population PF-562271 molecular weight of pregnant women. Methods: Prospective study. During a 5-year study period (July 2005-June 2010) 17,911 pregnant women underwent CTs with MGS (with fetal cardiac morphological evaluation performed by obstetricians in a tertiary hospital) as a screening method for DS. We evaluated the sensitivity and false positive rate (FPR) (95% confidence interval (CI)) of three screening methods for DS and all chromosomal disorders: CT, CT + MGS, and CT + fetal echocardiography. Results: A total of 17,911 cases were analyzed with 67 chromosome disorders and 45 DS cases being found. For DS, the CT sensitivity was 80% (95% CI; 68.3-91.7) (36/45) and 79.1% (95% CI; 69.4-88.8) (53/67) for all chromosome disorders, with a FPR of 4.2% (95% CI; 3.9-4.5) (752/17,866) and 4.1% (95% CI; 3.8-4.4) (735/17,844), respectively. For CT + MSG and CT + fetal echocardiography, the sensitivity Aurora Kinase inhibitor for DS was 93.3% (95% CI; 85.9-0.99) (42/45) and 95.5% (95% CI; 90.5-0.99) (64/67) for all chromosome disorders. The FPR for CT + MSG was 4.8% (95% CI; 4.5-5.1) (860/17,866) and 4.6% (95% CI; 4.3-4.9) (836/17,844), respectively. The

FPR of CT + fetal echocardiography was 4.4% (95% CI; 4.1-4.7) (792/17,866) for DS screening and 4.3% (95% CI; 4-4.6) (770/17,844) for chromosome abnormality screening. Conclusions: Fetal echocardiography is highly capable of identifying DS and other chromosomal disorders as a part of genetic sonography in stepwise sequential screening.”
“”"Phytoconstituents Isolated from Dichloromethane Fraction of Scutia buxifolia Reissek Stem Bark”". Fractionation of the dichloromethane soluble fraction from the ethanol extract of the stem bark of Scutia buxifolia Reissek (Rhamnaceae) led to the isolation of lupeol, P-sitosterol and stigmasterol. The structures of the isolates were elucidated by spectroscopic analysis and comparison with literature data.